News
Quotient Sciences to Recapitalize With Global Private Equity Firm Permira
Quotient Sciences to Recapitalize With Global Private Equity Firm Permira
Quotient is your answer.
Quotient is your answer.
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
-
How can I quickly achieve proof-of-concept?
Access Our ExpertiseAccess Our Expertise
Quotient is your answer.
How can I quickly achieve proof-of-concept?
Access Our Expertise -
How do I optimize my formulation?
Access Our Formulation ExpertiseAccess Our Formulation Expertise
Quotient is your answer.
How do I optimize my formulation?
Access Our Formulation Expertise -
How do I optimize and scale up my manufacturing process for late stage development?
Discover our Commercial CapabilitiesDiscover our Commercial Capabilities
Quotient is your answer.
How do I optimize and scale up my manufacturing process for late stage development?
Discover our Commercial Capabilities -
How do I conduct my regulatory clinical pharmacology studies?
Let Us Help YouLet Us Help You
Quotient is your answer.
How do I conduct my regulatory clinical pharmacology studies?
Let Us Help You -
How do I develop age-appropriate drug products?
Explore Our Pediatric CapabilitiesExplore Our Pediatric Capabilities
Quotient is your answer.
How do I develop age-appropriate drug products?
Explore Our Pediatric Capabilities
Our latest updates
Discover what’s happening at Quotient Sciences
-
Case Studies
Druggability Technologies
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT- 46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.
-
Webinar
From candidate selection through to proof-of-concept
Building a robust understanding of your API characteristics matched against your development programme goals, supports the efficient transition of drug products from candidate selection through to proof-of-concept. Starting @ 4pm (BST-UK), 11pm (ET), 8am (PT) and 6pm (BST-UK), 1pm (ET), 10am (PT)